Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

FUJIFILM Plans Boston, Massachusetts, Research & Manufacturing Campus

01/07/2021
FUJIFILM Corporation will invest $40 million in FUJIFILM Diosynth Biotechnologies, a world leading Contract Development and Manufacturing Organization for biologics, viral vaccines and viral vectors, to establish a new process development and manufacturing facility for viral vectors and advanced therapies in metro Boston, Massachusetts.

The new facility, the third location for viral vector CDMO services provided by FUJIFILM Diosynth Biotechnologies, is scheduled to begin process development operations in fall 2021 and will expand the company’s manufacturing capacity to support the growing viral vector sector, which is focused on using genes to treat or prevent disease.

"The strength of Fujifilm's Bio CDMO business lies in its wide-range of capabilities: process development for a variety of biopharmaceutical such as antibodies, recombinant protein, gene therapy, vaccines, oncolytic virus and more, along with flexible facilities that can adapt to small or large scale manufacturing of drug substances, formulation and packaging," said Takatoshi Ishikawa, senior executive vice president and chief life science officer, FUJIFILM Corporation. "We will continue to leverage our expertise in Bio CDMO to further accelerate our offerings in viral vectors and advanced therapies, with the ultimate goal of fulfilling unmet medical needs."

The new facility will house experimental and analytical equipment for viral vector and advanced therapy process development, with contract manufacturing services for early phase clinical trials beginning at the site in fall 2023.

"We are strategically establishing this facility in the greater-Boston area where there is a high concentration of biopharmaceutical companies and academia innovating in the field of advanced therapies," said Martin Meeson, CEO, FUJIFILM Diosynth Biotechnologies.

In 2014, FUJIFILM Corporation established a viral vector manufacturing offering at the FUJIFILM Diosynth Biotechnologies' site in Texas, U.S. As the market for viral vectors has continued to expand, Fujifilm has invested a further 13 billion yen ($120 million) in the Texas site to build a new process development facility and to expand existing manufacturing facilities. More recently, FUJIFILM Diosynth Biotechnologies announced an investment to provide process & analytical development and cGMP manufacturing of viral vectors in the U.K.

Exclusive Research